en
Scientific article
Open access
English

3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate

Published inJournal of bone and mineral research, vol. 39, no. 4, p. 473-483
Publication date2024-02-15
First online date2024-02-15
Abstract

Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1 year. DXA-based 3D modeling of the hip was used to assess estimated changes in cortical and trabecular bone parameters and map the distribution of 3D changes in bone parameters over time in patients from two randomized controlled clinical trials: FRAME (romosozumab vs placebo followed by denosumab) and ARCH (romosozumab vs alendronate followed by alendronate). For each study, data from a subset of ~200 women per treatment group who had total hip DXA scans at baseline and months 12 and 24 and had provided consent for future research were analyzed post hoc. 3D-SHAPER software v2.11 (3D-SHAPER Medical, Barcelona, Spain) was used to generate patient-specific 3D models from total hip DXA scans. Percentage changes from baseline to months 12 and 24 in areal BMD (aBMD), integral volumetric BMD (vBMD), cortical thickness, cortical vBMD, cortical surface BMD (sBMD), and trabecular vBMD were evaluated. Data from 377 women from FRAME (placebo, 190; romosozumab, 187) and 368 women from ARCH (alendronate, 185; romosozumab, 183) with evaluable 3D assessments at baseline and months 12 and 24 were analyzed. At month 12, treatment with romosozumab vs placebo in FRAME and romosozumab vs alendronate in ARCH resulted in greater increases in aBMD, integral vBMD, cortical thickness, cortical vBMD, cortical sBMD, and trabecular vBMD (P < 0.05 for all). At month 24, cumulative gains in all parameters were greater in the romosozumab-to-denosumab vs placebo-to-denosumab sequence and romosozumab-to-alendronate vs alendronate-to-alendronate sequence (P < 0.05 for all). 3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.

eng
Keywords
  • Cortical surface BMD
  • Cortical thickness
  • Cortical volumetric BMD
  • Osteoporosis
  • Trabecular volumetric BMD
Citation (ISO format)
LEWIECKI, E Michael et al. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. In: Journal of bone and mineral research, 2024, vol. 39, n° 4, p. 473–483. doi: 10.1093/jbmr/zjae028
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0884-0431
25views
4downloads

Technical informations

Creation03/26/2024 8:32:47 AM
First validation06/10/2024 8:28:15 AM
Update time06/10/2024 8:28:15 AM
Status update06/10/2024 8:28:15 AM
Last indexation06/10/2024 8:28:35 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack